622 related articles for article (PubMed ID: 23465067)
1. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
[TBL] [Abstract][Full Text] [Related]
2. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
Scand J Rheumatol; 2009; 38(6):439-44. PubMed ID: 19922018
[TBL] [Abstract][Full Text] [Related]
3. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
5. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.
Klimiuk PA; Sierakowski S; Domysławska I; Fiedorczyk M; Chwiećko J
Arch Immunol Ther Exp (Warsz); 2004; 52(1):36-42. PubMed ID: 15053231
[TBL] [Abstract][Full Text] [Related]
6. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors.
Hjeltnes G; Hollan I; Førre Ø; Wiik A; Lyberg T; Mikkelsen K; Agewall S
J Rheumatol; 2012 Jul; 39(7):1341-7. PubMed ID: 22660798
[TBL] [Abstract][Full Text] [Related]
7. Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.
Bergman M; De G; Ganguli A; Signorovitch J; Bao Y
J Med Econ; 2015 Jan; 18(1):37-44. PubMed ID: 24841451
[TBL] [Abstract][Full Text] [Related]
8. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
[TBL] [Abstract][Full Text] [Related]
9. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis.
Klimiuk PA; Fiedorczyk M; Sierakowski S; Chwiecko J
Scand J Rheumatol; 2007; 36(5):345-50. PubMed ID: 17963163
[TBL] [Abstract][Full Text] [Related]
10. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
[TBL] [Abstract][Full Text] [Related]
11. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
12. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
[TBL] [Abstract][Full Text] [Related]
13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
Alonso-Ruiz A; Pijoan JI; Ansuategui E; Urkaregi A; Calabozo M; Quintana A
BMC Musculoskelet Disord; 2008 Apr; 9():52. PubMed ID: 18419803
[TBL] [Abstract][Full Text] [Related]
15. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
17. Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy.
Rodriguez-Jimenez NA; Garcia-Gonzalez CE; Ayala-Lopez KP; Trujillo-Hernandez B; Aguilar-Chavez EA; Rocha-Muñoz AD; Vasquez-Jimenez JC; Olivas-Flores E; Salazar-Paramo M; Corona-Sanchez EG; Vazquez-Del Mercado M; Varon-Villalpando E; Cota-Sanchez A; Cardona-Muñoz EG; Gamez-Nava JI; Gonzalez-Lopez L
Biomed Res Int; 2014; 2014():510305. PubMed ID: 25243145
[TBL] [Abstract][Full Text] [Related]
18. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
19. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
20. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]